Laparoscopic radical hysterectomy using robotic surgical system (da Vinci Surgical System; DVSS)

Laparoscopic radical hysterectomy using robotic surgical system (da Vinci Surgical System; DVSS) - Robot-assisted radical hysterectomy

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000022278

Enrollment

100

Registered

2016-05-11

Start date

2016-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cervical cancer

Interventions

use of the robot for endoscopic surgery

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: cervical cancer (squamous cell carcinoma FIGO Stages IB1 - llB , or adenocarcinoma FIGO Stages IA2 - IIB without metastasis of lymph nodes and intracorporeal organs)

Exclusion criteria

Exclusion criteria: 1) patients having an active double cancer 2) a woman who become pregnant or may become pregnant, or a nursing woman 3) patients with mental disorders 4) morbid obese patients (Body Mass Index: BMI >= 35) 5) patients received neoadjuvant chemotherapy 6) patients that it was judged that it was inadequate to participate in this study due to others

Design outcomes

Primary

Measure	Time frame
success operation with a little blood loss	—

Secondary

Measure	Time frame
the operation time, the console time, No. of lymph nodes resected, the appropriateness of extracted specimen, the ratio of blood transfusion, the reserve ratio of autologous blood, the urinary function, the success rate of robot-assisted radical hysterectomy, the rate of conversion to laparotomy, postoperative courses (onset of postoperative oral ingest, duration of postoperative hospital stay), postoperative QOL measured by EQ-5D, overall survival, relapse-free survival, the occurrence of perioperative adverse events, the occurrence of postoperative adverse events, the occurrence of late adverse events, the defect failure of DVSS	—

Measure

Time frame

the operation time, the console time, No. of lymph nodes resected, the appropriateness of extracted specimen, the ratio of blood transfusion, the reserve ratio of autologous blood, the urinary function, the success rate of robot-assisted radical hysterectomy, the rate of conversion to laparotomy, postoperative courses (onset of postoperative oral ingest, duration of postoperative hospital stay), postoperative QOL measured by EQ-5D, overall survival, relapse-free survival, the occurrence of perioperative adverse events, the occurrence of postoperative adverse events, the occurrence of late adverse events, the defect failure of DVSS

—

Countries

Japan

Contacts

Public ContactKaori Nakamichi

Tokyo Medical University Hospital Department of Obstetrics and Gynecology

n-kaori@tokyo-med.ac.jp03-3342-6111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026